How much funding has BeiGene raised?

BeiGene has raised $2.8B in total funding, most recently a Corporate Round.

Who are BeiGene's investors?

BeiGene's investors include Amgen, Goldman Sachs, Morgan Stanley.

Where is BeiGene headquartered?

BeiGene is headquartered in Cambridge, Massachusetts, United States.

What industry is BeiGene in?

BeiGene operates in Biotech, Oncology, Healthcare.

BeiGene

IPO

One World. One Goal.

Public · Cambridge, United States · Founded 2010 · $2.8B raised

Biotech

Oncology

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 10001+
Founded: 2010
Business Model: B2B
Website: beigene.com

Total Funding: $2.8B
Last Round: $2.8B Corporate RoundJan 2020
Rounds: 1
Type: Public

About

BeOne Medicines (formerly BeiGene) is a global oncology company committed to discovering and developing innovative treatments to make a meaningful difference for cancer patients worldwide. With a portfolio of approved medicines across hematologic and solid tumor cancers including BTK inhibitors and anti-PD-1 therapies, BeOne operates research facilities and commercial operations in over 45 countries. The company completed its rebrand from BeiGene to BeOne Medicines in 2025.

Summary

BeiGene is a Biotech company based in Cambridge, United States, founded in 2010. It has raised $2.8B in total across 1 round, most recently a $2.8B Corporate Round round in Jan 2020. Investors include Amgen, Goldman Sachs and Morgan Stanley.

LinkedIn X (Twitter)